World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.): Third edition of the guideline for evaluating efficacy of anthelmintics in ruminants (bovine, ovine, caprine).

This guideline is aimed at those who are involved in the assessment of anthelmintic efficacy in ruminant livestock species (bovine, ovine and caprine). The intent is to provide a framework that can be adopted worldwide for the testing of anthelmintics in ruminants, such that studies carried out in different countries can be compared and thereby unnecessary duplication can be reduced. Recommendations are made for the selection, housing and feeding of study animals, the type of studies required, the method used to conduct those studies, the assessment of results and the standards for defining anthelmintic efficacy.

World association for the advancement of veterinary parasitology (WAAVP): Second edition of guidelines for evaluating the efficacy of anthelmintics in poultry.

This revision of the original poultry guidelines has been prepared to assist in the planning, conduct and interpretation of studies designed to assess the anthelmintic efficacy of drugs (newly discovered or currently used) against helminth parasites of chickens and turkeys. The original set of poultry guidelines was published in 2003. The current version provides an update on procedures to study and quantify the most important helminth parasites of chickens and turkeys, and to integrate these poultry guidelines with a new series of general, reflective and host-specific guidelines relative to assessing anthelmintic efficacy in production and companion animals. General considerations required for the conduct of studies designed to evaluate anthelmintics regardless of animal host such as the selection of study animals, animal housing, feeding, study design, record keeping and statistical analysis are for the most part provided in the newly published general guidelines. Taken together, the general and poultry guidelines should help investigators and others design and conduct studies and evaluate data concerned with determining the efficacy and safety of anthelmintics in chickens and turkeys. Additionally, this revision draws attention to several timely considerations inherent to anthelmintic evaluations such as the need to properly collect helminth specimens for subsequent determinations (e.g. species and stage verification, helminth genotyping). The investigations addressed herein, will most likely provide the very first public record of a new product's abilities to effectively reduce targeted, helminth infections in animals, and particular attention should be focused on study excellence and accuracy. Due to changes in consumer preferences, and new regulatory requirements, poultry husbandry, especially regarding laying hens, has changed immensely in many countries since the publication of the first poultry guidelines. These changes have generally allowed for a much greater exposure of birds to the source of helminth challenge (litter and fields as opposed to cages). Parasitic helminthiosis of poultry has therefore greatly increased in incidence and magnitude; changes that accentuate the need for more effective anthelmintic intervention and an update on the means of determining anthelmintic efficacy.

Distribution of Four Parasitic Helminth Species in One Pen-Free, Egg-Laying Housing Facility, and the Corresponding Efficacy of Nutraceutical and Pharmaceutical Administrations.

In the spring of 2019, adult (75 wk old) brown laying hens from a commercial, pen-free, egg-laying facility (11,000 birds per house) located in northwest Arkansas were obtained for the purposes of sourcing robust and evenly dispersed cestode infections for anticipated anthelmintic evaluations. To that end, four birds from each of six discrete sites (northwest, northcentral, northeast, southwest, southcentral, and southeast) in one production barn were obtained on two occasions, 8 days apart, and necropsied for helminth counts. A definite, repeated, location-to-location variation in infection incidence and magnitude was seen for each of the two cestode parasite species present and for one of the two nematode parasite species present. Burdens of Ascaridia galli were generally similar regardless of bird location, with site-specific mean totals per bird over both sampling days between 31 and 80. For the remaining helminths, infections were greatest for birds from the southern half of the building as opposed to the northern and from the western end of the barn as opposed to the central or eastern portions. Location-specific mean worm burdens over both sample dates ranged from 340 to 1133 (Heterakis gallinarum), 14 to 277 (Raillietina cesticillus), and 1 to 35 (Choanotaenia infundibulum). The greatest individual bird infections were 299 (A. galli), 3575 (H. gallinarum), 1015 (R. cesticillus), and 102 (C. infundibulum). The above counts are for all developmental stages combined (A. galli and H. gallinarum) and for scolexes only (R. cesticillus and C. infundibulum), as determined via standard collection and quantification procedures using both intestinal contents and overnight soaks. Immediately before the mapping study outlined above, birds were obtained from the east end of the source barn and used for the nematocidal evaluation of fenbendazole in the water (5 mg/kg body weight [BW] for 1 day), levamisole in the water (8 mg/kg BW for each of 2 days), herbal mixture in the feed (1 gm/4.5 kg BW each day for 5 days), diatomaceous earth (2% of total feed for 10 days), and a nutraceutical mixture feed supplement (2% of feed for 7 days). Based on arithmetic means for adult forms, control trial efficacies for A. galli and H. gallinarum were 0% and 12% for the nutraceutical feed additive, 0% and 22% for the diatomaceous earth feed additive, 0% and 26% for dietary herbals, 87% and 63% for levamisole, and 82% and 84% for fenbendazole, respectively. Only adult burdens of A. galli and H. gallinarum for fenbendazole- and levamisole-treated birds were significantly different from control bird levels (P ≤ 0.05).

Growth promoting hormonal implant pellets coated with a polymeric, porous film promote weight gain by grazing beef heifers and steers for up to 200 days.

Two studies evaluated growth promoting effects of implant pellets (IP), each containing 3.5 mg estradiol benzoate (EB) and 25 mg trenbolone acetate (TBA), to which a polymeric, porous coating was applied. Trial 1 evaluated performance of heifers (n = 70/treatment, initial BW = 188 ± 2.2 kg) and steers (n = 70/treatment, initial BW = 194 ± 2.2 kg) implanted subcutaneously in the ear with 0 (SC), 2 (2IP), 4 (4IP), or 6 (6IP) pellets that delivered EB/TBA (mg/mg) doses of 0/0, 7/50, 14/100, and 21/150, respectively, over grazing periods of 202 d (heifers) or 203 d (steers). Animals received experimental treatments on d 0 and over the grazing period were managed as single groups by sex in a rotational grazing system. When pasture forage availability became limited, cattle were supplemented with preserved forage but not concentrate supplements. Weight gains by heifers treated with 2IP, 4IP, and 6IP were greater (P < 0.05) than SC heifers but not different from each other. Weight gains by steers treated with 2IP, 4IP, and 6IP were greater than SC steers (P < 0.05), and ADG by steers treated with 6IP was greater (P < 0.05) than steers given 2IP or 4IP. Trial 2 was a multisite grazing study performed with heifers and steers to compare ADG after treatment with one 6-pellet, coated implant delivering 21 mg EB and 150 mg TBA (6IP) to sham treated negative controls (SC) over a grazing period of at least 200 d. A completely random design was used at each site, with the goal to treat 70 cattle per site, treatment, and sex; data were pooled across sites. Heifers (n = 558, initial BW = 229 ± 16 kg) and steers (n = 555, initial BW = 235 ± 20 kg) grazed in rotational programs consistent with regional practices for an average of 202 d. When necessary, cattle were supplemented with preserved forage, but no concentrate supplements were fed. Over 202 d, ADG by heifers treated with 6IP was 11.3% greater (P = 0.0035) than SC heifers (0.64 ± 0.06 kg/d), and ADG by steers treated with 6IP was 17.2% greater (P = 0.0054) than SC steers (0.66 ± 0.08 kg/d). In neither study was there evidence that concurrent therapeutic treatments or abnormal health observations were influenced by experimental treatments. These studies demonstrated that a 6-pellet implant with a polymeric, porous coating that delivers 21 mg EB and 150 mg TBA improved ADG by grazing heifers and steers for at least 200 d compared to sham-implanted negative controls.

Control trial and fecal egg count reduction test determinations of nematocidal efficacies of moxidectin and generic ivermectin in recently weaned, naturally infected calves.

An anthelmintic efficacy study was performed with young, naturally infected beef-type calves obtained at local farms. Presumably, the study calves had been recently weaned and had not been treated with a parasiticide prior to study acquisition. After blocking the 24 study calves in accordance with calculated Cooperia spp EPG counts, the calves were randomly allocated within each block to one of four treatment groups, resulting in 6 animals per treatment group (untreated controls, topical ivermectin at the rate of 500 mcg/kg BW [Noromectin Pour-On(®) Norbrook], topical moxidectin at the rate of 500 mcg/kg BW [Cydectin Pour-On(®) Boehringer Ingelheim Vetmedica (BIVM)] and injectable moxidectin at the rate of 200 mcg/kg BW [Cydectin(®) BIVM]. After treatment, the animals were penned by treatment group until necropsy. Fecal, strongyle egg count reduction percentages at 2 days post-treatment were 13, 52, 81 and 93 for control, topical ivermectin, topical moxidectin and injectable moxidectin treatment groups, respectively. In the same order as above, egg count reduction percentages at necropsy (15-18 days post-treatment) were -14, 91, 94 and 97. Based on geometric means for worm burdens quantified at necropsy, anthelmintic efficacies ranged from 96 to 100% for adult Oesophagostomum radiatum, Ostertagia ostertagi, Haemonchus placei and Trichostrongylus axei. Against adult Nematodirus helvetianus, percent efficacies based on geometric means were 56.7, 98.3 and 82.2 for topical ivermectin, topical moxidectin and injectable moxidectin, respectively; an observation that is guarded, as only 5 control animals were infected with adult N. helvetianus. Respective anthelmintic efficacies (%'s) against adult Cooperia oncophora and C. punctata were 93.0 and 73.4 (topical ivermectin), 99.3 and 99.9 (topical moxidectin) and 46.1 and 93.6 (injectable moxidectin). Judging from these data, it appears that treatment of calves soon after weaning with topical moxidectin is effective (>90% efficacy) for all common nematodes in cattle, but injectable moxidectin and topical ivermectin have limited effectiveness against Cooperia spp. With Cooperia spp and H. placei infections, the fecal egg count reduction test and the control trial determinations of anthelmintic effectiveness were in disagreement regarding injectable moxidectin and topical ivermectin.

An eprinomectin extended-release injection formulation providing nematode control in cattle for up to 150 days.

A series of 10 dose confirmation studies was conducted to evaluate the persistent activity of an extended-release injectable (ERI) formulation of eprinomectin against single point challenge infections of gastrointestinal and pulmonary nematodes of cattle. The formulation, selected based on the optimal combination of high nematode efficacy, appropriate plasma profile, and satisfactory tissue residue levels, includes 5% poly(D,L-lactide-co-glycolic)acid (PLGA) and is designed to deliver eprinomectin at a dose of 1.0mg/kg bodyweight. Individual studies, included 16-30 cattle blocked based on pre-treatment bodyweight and randomly allocated to treatment with either ERI vehicle or saline (control), or the selected Eprinomectin ERI formulation. Treatments were administered once at a dose volume of 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder. In each study, cattle were challenged with a combination of infective stages of gastrointestinal and/or pulmonary nematodes 100, 120 or 150 days after treatment and were processed for parasite recovery according to standard techniques 25-30 days after challenge. Based on parasite counts, Eprinomectin ERI (1mg eprinomectin/kg bodyweight) provided >90% efficacy (p<0.05) against challenge with Cooperia oncophora and Cooperia surnabada at 100 days after treatment; against challenge with Ostertagia ostertagi, Ostertagia lyrata, Ostertagia leptospicularis, Ostertagia circumcincta, Ostertagia trifurcata, Trichostrongylus axei, and Cooperia punctata at 120 days after treatment; and against challenge with Haemonchus contortus, Bunostomum phlebotomum, Oesophagostomum radiatum and Dictyocaulus viviparus at 150 days after treatment. Results of a study to evaluate eprinomectin plasma levels in cattle treated with the Eprinomectin ERI formulation reveal a characteristic second plasma concentration peak and a profile commensurate with the duration of efficacy. These results confirm that the Eprinomectin ERI formulation can provide high levels of parasite control against a range of nematodes of cattle for up to 5 months following a single treatment.

Persistent efficacy and production benefits following use of extended-release injectable eprinomectin in grazing beef cattle under field conditions.

Seven studies were conducted in commercial grazing operations to confirm anthelmintic efficacy, assess acceptability, and measure the productivity response of cattle to treatment with eprinomectin in an extended-release injectable formulation (ERI) when exposed to nematode infected pastures for 120 days. The studies were conducted under one protocol in the USA in seven locations (Arkansas, Idaho, Louisiana, Minnesota, Missouri, Oregon, and Wisconsin). Each study had 67-68 naturally infected animals for a total of 475 (226 female, 249 male castrate) Angus or beef-cross cattle. The animals weighed 133-335 kg prior to treatment and were approximately 3-12 months of age. The studies were conducted under a randomized block design based on pre-treatment body weights to sequentially form 17 replicates of four animals each within sex in each study. Animals within a replicate were randomly assigned to treatments, one to Eprinomectin ERI vehicle (control) and three to Eprinomectin ERI (5%, w/v eprinomectin). Treatments were administered at 1 mL/50 kg body weight once subcutaneously anterior to the shoulder. All animals in each study grazed one pasture throughout the observation period of 120 days. Cattle were weighed and fecal samples collected pre-treatment and on 28, 56, 84, and 120 days after treatment for fecal egg and lungworm larval counts. Positive fecal samples generally were cultured en masse to determine the nematode genera attributable to the gastrointestinal helminth infection. Bunostomum, Cooperia, Haemonchus, Nematodirus, Oesophagostomum, Ostertagia, and Trichostrongylus, when present, were referred to as strongylids. At all post-treatment sampling intervals, Eprinomectin ERI-treated cattle had significantly (P<0.05) lower strongylid egg counts than vehicle-treated controls, with ≥95% reduction after 120 days of grazing. Over this same period, Eprinomectin ERI-treated cattle gained more weight (43.9 lb/head) than vehicle-treated controls in all studies. This weight gain advantage was significant (P<0.05) in six of the studies with the Eprinomectin ERI-treated cattle gaining an average of 42.8% and the control cattle gaining 33.1% of their initial weight. No adverse reactions were observed in the treated animals.

The efficacy of eprinomectin extended-release injection against naturally acquired nematode parasites of cattle, with special regard to inhibited fourth-stage Ostertagia larvae.

The efficacy of eprinomectin in an extended-release injection (ERI) formulation in the treatment of cattle harboring naturally acquired nematode populations (including inhibited nematodes) was evaluated. Five studies were conducted under a similar protocol in the USA, the UK, and in Germany. All study animals were infected by grazing naturally contaminated pastures. The adequacy of pasture infectivity was confirmed by examining tracer calves prior to allocation and treatment of the study animals. The cattle were of various breeds or crosses, weighing 79-491 kg, and aged approximately 6-15 months. In each study, 20 animals were infected by grazing, and then removed from pasture and housed in a manner to preclude further nematode infections for 8-16 days until treatment. Animals were blocked based on descending pre-treatment body weight and randomly allocated to one of two treatments: ERI vehicle (control) at 1 mL/50 kg body weight or eprinomectin 5% (w/v) ERI at 1 mL/50 kg body weight (1.0 mg eprinomectin/kg). Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. For parasite recovery and count, all study animals were humanely euthanized 14/15 days after treatment. Cattle treated with eprinomectin ERI had significantly (p<0.05) fewer of the following nematodes than the controls with overall reduction of parasite counts of ≥94%: adult Dictyocaulus viviparus, Capillaria spp., Cooperia oncophora, Cooperia pectinata, Cooperia punctata, Cooperia surnabada, Haemonchus placei, Nematodirus helvetianus, Oesophagostomum radiatum, Ostertagia lyrata, Ostertagia ostertagi, Trichostrongylus axei, Trichostrongylus colubriformis, Trichuris discolor, Trichuris skrjabini, and Trichuris spp.; developing fourth-stage larvae of Ostertagia spp. and Trichostrongylus spp.; and inhibited fourth-stage larvae of Cooperia spp., Haemonchus spp., Nematodirus spp., Oesophagostomum spp., Ostertagia spp., and Trichostrongylus spp. Animal treatments were well accepted, with no adverse reactions to treatment observed in any study animals. The results of this series of controlled studies demonstrated high therapeutic efficacy and acceptability of eprinomectin ERI against pulmonary nematodes and a wide range of gastrointestinal parasitic infections, including inhibited gastrointestinal nematodes, in cattle.

Nematode burdens of pastured cattle treated once at turnout with eprinomectin extended-release injection.

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated against infections with third-stage larvae or eggs of gastrointestinal and pulmonary nematodes in cattle under 120-day natural challenge conditions in a series of five studies conducted in the USA (three studies) and in Europe (two studies). For each study, 30 nematode-free (four studies) or 30 cattle harboring naturally acquired nematode infections (one study) were included. The cattle were of various breeds or crosses, weighed 107.5-273 kg prior to treatment and aged approximately 4-11 months. For each study, animals were blocked based on pre-treatment bodyweight and then randomly allocated to treatment: ERI vehicle (control) at 1 mL/50 kg bodyweight or Eprinomectin 5% (w/v) ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg) for a total of 15 and 15 animals in each group. Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. In each study, all animals grazed one naturally contaminated pasture for 120 days. At regular intervals during the studies, fecal samples from all cattle were examined for nematode egg and larval counts. In four studies pairs of tracer cattle were used to monitor pasture infectivity at 28-day intervals before and/or during the grazing period. All calves were weighed before turnout onto pasture and at regular intervals until housing on Day 120. For parasite recovery, all study animals were humanely euthanized 27-30 days after removal from pasture. Cattle treated with Eprinomectin ERI had significantly (p<0.05) fewer strongylid eggs (≤1 egg per gram; egg count reduction≥94%) than the control cattle and zero lungworm larvae at each post-treatment time point. At euthanasia, cattle treated with Eprinomectin ERI had significantly (p<0.05) fewer of the following nematodes than the ERI vehicle-treated (control) cattle with overall reduction of nematode counts by >92%: Dictyocaulus viviparus (adults and fourth-stage larvae (L4), Bunostomum phlebotomum, Cooperia curticei, Cooperia oncophora, Cooperia punctata, Cooperia surnabada, Cooperia spp. inhibited L4, Haemonchus contortus, Haemonchus placei, Haemonchus spp. inhibited L4, Nematodirus helvetianus, Nematodirus spp. inhibited L4, Oesophagostomum radiatum, Oesophagostomum spp. inhibited L4, Ostertagia leptospicularis, Ostertagia lyrata, Ostertagia ostertagi, Ostertagia spp. inhibited L4, Trichostrongylus axei, Trichostrongylus colubriformis, Trichostrongylus spp. inhibited L4, Trichuris discolor, and Trichuris ovis. Over the 120-day grazing period, Eprinomectin ERI-treated cattle gained between 4.8 kg and 31 kg more weight than the controls. This weight gain advantage was significant (p<0.05) in three studies. All animals accepted the treatment well. No adverse reaction to treatment was observed in any animal in any study.

Fecal egg count reduction and control trial determinations of anthelmintic efficacies for several parasiticides utilizing a single set of naturally infected calves.

In this study, a single set of naturally infected calves was used for the conduct of a fecal egg count reduction test (FECRT) immediately followed by a control trial; all, to evaluate the efficacies of several commonly used, non-generic anthelmintics. Ten animals were allocated into each of the five treatment groups; untreated control (UTC), injectable 1% moxidectin given at 0.2 mg kg(-1)BW (MXD), injectable 1% ivermectin given at 0.2 mg kg(-1)BW (IVM), 9.06% oxfendazole given orally at 4.5 mg kg(-1)BW (OXF), and 10.0% fenbendazole given orally at 5.0 mg kg(-1)BW (FBZ). Confinement of animals to clean, concrete-floored pens was initiated on day -7 and continued until animal necropsy (2 animals were necropsied per treatment group per day on days 35-39 for nematode collections). All treatments were given on day 0, and the FECRT was conducted on all animals until necropsy. From days 2 to 14, FECR %'s for the combined strongyle egg counts were >or=90% for all anthelmintic groups. At the time of necropsy, FECRT %'s for the combined strongyle egg counts continued to be >or=90% for all treatments with the exception of IVM (84%). After adjustment of the strongyle egg counts in accordance with coproculture larvae percentages, FECRT %'s at the time of necropsy for Haemonchus, Ostertagia and Cooperia were found to be >or=94% for MXD and OXF, but <90% for FBZ (Ostertagia) and IVM (Haemonchus and Cooperia). At necropsy, more than six of the ten untreated animals were infected with Ostertagia ostertagi (adults, EL(4) and LL(4)), and adult Haemonchus placei, Trichostrongylus axei, Cooperia oncophora, C. surnabada and C. punctata. Based on geometric means: all of the above populations were removed by >or=96% by MXD; were removed by >or=90% by IVM except for O. ostertagi LL(4) (81.9%), C. oncophora and C. surnabada adults (77.4%) and C. punctata adults (84.8%); were removed by >or=90% by OXF except for O. ostertagi adults, EL(4) and LL(4) (89.9, 70.2 and 48.1%, respectively); and were removed by >or=90% by FBZ except for O. ostertagi adults, EL(4) and LL(4) (72.5, 0.0 and 21.9%, respectively). Judging from the above data, FECR and control trial results can be extremely similar given the proper experimentation and, despite varied degrees of nematode resistance, targeted nematode burdens commonly carried by Midwestern beef cattle are effectively removed by the parasiticides that are available today.

Effectiveness evaluation of several cattle anthelmintics via the fecal egg count reduction test.

Utilizing groups of cograzed, naturally infected beef-type heifers, three fecal egg count reduction tests were conducted in the later months of 2007 at the University of Arkansas. Each test was 28 days in length consisting of individual animal fecal nematode egg counts and coprocultures. Both original and generic ivermectin injectable formulations were used in two of the tests at 0.2 mg/kg BW, with FECR percentages never exceeding 90% in either test. Oral fenbendazole was evaluated at 5 and 10 mg/kg BW, with FECR%'s exceeding 90% on all occasions, but with a precipitous drop when recently treated animals were treated at the lower dose. Evaluated in one test, injectable moxidectin given at 0.2 mg/kg BW resulted in egg count reductions of 96-92% (days 7 to 28). Also evaluated in one test, albendazole delivered orally at 10 mg/kg BW was 98% and 97% effective at 17 and 28 days post-treatment. For all tests, coprocultures conducted post-treatment contained only Cooperia spp. larvae (benzimidazole use), relatively unmodified percentages of Cooperia spp. and Haemonchus spp. larvae (ivermectin use), and primarily Cooperia spp. larvae with a small percentage of Haemonchus spp. larvae (moxidectin use).

Fecal egg count reductions and performance effect of Dectomax, Cydectin, and Cydectin plus Synanthic as used in feedlot steers.

A study was conducted to assess the effectiveness (fecal egg count reductions) and benefit (improvement in feed efficiency, average daily gain, health, and so forth) of a macrocyclic lactone (moxidectin [Cydectin Injectable] or doramectin [Dectomax 1% Injectable]) alone or in combination with a benzimidazole (oxfendazole [Synanthic Bovine Dewormer]) as used in steers upon their arrival at a feedlot. The cattle were kept in the feedlot for 181 days. Only minor differences in fecal egg count reductions were seen among treatments, with all egg counts reduced by more than 98% by 28 days posttreatment. Likewise, no statistically significant differences among treatments were seen in terms of animal performance (feed efficiency, intake, gain, morbidity, mortality, and carcass quality). All three treatment regimens appear to be comparable in decreasing nematode burdens and the consequences thereof in feedlot cattle.

A field trial evaluation of the effectiveness and benefit of cydectin long-acting injectable and ivomec injectable as used one time in grazing stocker cattle.

Use of moxidectin long-acting injectable and ivermectin injectable in female Bos taurus beef-type calves was evaluated in terms of efficacy (fecal egg counts) and performance parameters (weight gain). In this 150-day study, moxidectin-treated calves gained 20% more weight than did ivermectin-treated and control calves. Mean fecal egg count reductions ranged from 76.7 to 99.0 for moxidectin and -0.8 to 83.4 for ivermectin. Moxidectin long-acting injection provided efficacious (immediate as well as long-term) egg count suppressions as well as enhanced animal productivity (weight gains). The study also showed that Cooperia spp appear poised to present the most immediate challenges once long-acting macrocyclic lactone treatments become available.

Dose determination of the persistent activity of moxidectin long-acting injectable formulations against various nematode species in cattle.

The effectiveness, safety and production-enhancing benefit (improved weight gains) of moxidectin long-acting injection given subcutaneously in the ear at the rates of 0.75, 1.0 and 1.5mg/kg bw were evaluated in three studies under common protocol. The only adverse reaction to treatment was a mild (<2 tablespoons in volume), and for the most part transient (<28 days for the treatment rate of 1.0mg/kg bw) injection site swelling as noted in a minority of the animals (12.2% of the animals treated at the rate of 1.0mg/kg bw). Regardless of study site, post-treatment interval or dose rate, average daily gains were improved over control cattle by approximately 33%. Reductions in strongyle EPG counts relative to controls were > or = 90% for all dose rates of moxidectin for a post-treatment period of 42 days (Wisconsin), 84 days (Arkansas) and 140 days (Louisiana). In Arkansas and Louisiana, the majority (>80%) of post-treatment strongyle eggs, as determined by coproculture, were Cooperia spp. As determined by sequential necropsies, periods of continuous, post-treatment protection (> or = 90% efficacy in at least two out of three studies) for moxidectin long-acting injection given at the rate of 1.0 mg/kg bw were 90 days (adult Haemonchus spp.), 120 days (Dictyocaulus viviparus and adult Ostertagia and Oesophagostomum) and 150 days (Ostertagia spp. EL4).

Effects of subcutaneous injections of a long acting moxidectin formulation in grazing beef cattle on parasite fecal egg reduction and animal weight gain.

Trials were conducted in Arkansas, Idaho, Illinois and Wisconsin using a common protocol to evaluate effectiveness and safety of a long acting (LA), oil-based injectable formulation of moxidectin in beef cattle grazing spring and/or summer pastures. At each site, 150 cattle (steers and/or heifers) were blocked based on pretreatment fecal strongyle egg counts (EPG) and then randomly assigned to treatments within blocks. Presence of naturally acquired parasitic infections, confirmed by presence of parasite eggs in feces, was a prerequisite for study enrollment. Within each block of three animals, two received moxidectin LA injectable on day 0 at a dosing rate of 1.0 mg moxidectin/kg b.w. into the dorsal aspect of the proximal third of the ear, and one received a placebo control treatment. Cattle were weighed before treatment and on day 55 or 56 (55/56) after treatment. Fecal samples were also collected from 10 randomly selected blocks of animals at each site on days 14, 28 and 55/56 for EPG quantification. Average daily gain (ADG) was computed over the posttreatment period. Data pertaining to ADG and EPG were combined across sites and analyzed by mixed model analysis of variance to assess the fixed effect of treatment and random effects of site, block within site and the treatment by site interaction. Compared to placebo-treated controls, the geometric means of fecal EPG counts from cattle treated with moxidectin LA injectable were reduced 99.8% 14 days after treatment, 99.1% 28 days after treatment and 96.7% 55/56 days after treatment. Rate of weight gain by cattle treated with moxidectin LA injectable was 0.59 kg/day, or 23% (0.11 kg/day) more than placebo-treated controls (P<0.05). None of the cattle treated with moxidectin LA injectable exhibited signs of macrocyclic lactone toxicosis. Summarized across all study sites, proportions of cattle that received concurrent therapeutic treatments were similar among treatment groups. Study results demonstrate that moxidectin cattle LA injectable administered at a dosing rate of 1.0 mg moxidectin/kg b.w. to grazing beef cattle was effective and safe.

World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the effectiveness of anthelmintics in chickens and turkeys.

These guidelines have been prepared to assist in the planning, operation and interpretation of studies designed to assess the effectiveness of drugs against helminth parasites of chickens and turkeys. They are the first to be compiled under the auspices of the World Association for the Advancement of Veterinary Parasitology (WAAVP) for these parasites. The advantages and disadvantages of the widely used critical and controlled tests are discussed. Information is provided on the selection of animals for experiments, animal housing, feed, dose determination studies, confirmatory and field trials, record keeping and necropsy procedures. This document should help investigators and those involved in product approval and registration in conducting and evaluating studies concerned with determining the effectiveness and safety of anthelmintic drugs.

Subclinical effects and fenbendazole treatment of turkey ascaridiasis under simulated field conditions.

Under simulated natural conditions of bird production and parasite challenge, the effects of ascaridiasis and the effectiveness of fenbendazole treatment (6-day regimes in the feed at 16 ppm) were documented. Birds were artificially challenged with ascarid larvae on a daily basis from day 35 to 112, with bird grow out ending on day 119. Experimental groups, on a per pen basis, were infected control, treated with fenbendazole at days 63-69, treated with fenbendazole at days 63-69 and days 91-97, and uninfected control. In the same order as above, and on an experimental group mean bird basis, final weights were 13.34, 13.47, 13.59, and 13.78 kg, average daily gains from day 7 to day 119 were 117.8, 118.9, 120.1, and 121.8 g, and units gained per unit of feed consumed from day 7 to day 119 were 0.337, 0.341, 0.347, and 0.362. Infected control bird mean Ascaridia dissimilis burdens, with all stages combined, ranged from 351.1 on day 63 to 117.2 on day 91, levels seen commonly with naturally infected commercial turkeys. Trial data dearly indicated that moderate A. dissimilis burdens negatively impacted animal performance (average daily gains and feed efficiencies) and that these parasite burdens are effectively removed by fenbendazole treatment.

Cyathostome fecal egg count trends in horses treated with moxidectin, ivermectin or fenbendazole.

Commercial preparations of fenbendazole (Safe-Guard, Intervet), ivermectin (Eqvalan, Merial) or moxidectin (Quest, Fort Dodge) were administered once to horses scheduled for routine parasiticide treatment. In total, 93 horses from six cooperating farms were used in the study. Computer generated, random allocation of horses to treatment group was conducted at each farm. Fecal egg counts were determined for all horses on trial days 0, 56, 84 and 112, with corresponding calendar dates that were unique to each farm. Only strongyle egg counts from animals which were positive at day 0 were used for analysis of variance and comparisons. Counts for the three treatment groups were similar at day 0, moxidectin

Dose confirmation of moxidectin pour-on against natural nematode infections in lactating dairy cows.

The nematocidal effectiveness of moxidectin, administered topically at the rate of 500 mcg/kg BW, was determined for lactating dairy cows. Naturally infected animals were given either topical vehicle or moxidectin (Cydectin Pour-On Fort Dodge Animal Health) at the rate of 1 ml/10 kg BW (10 animals per treatment group), and sacrificed 14-18 days post-treatment for nematode enumeration. 100% efficacies were recorded for Ostertagia lyrata males, Cooperia punctata males and Oesophagostomum radiatum L4, with treatment group differences in geometric means significant (P < 0.05) for all. Populations of Trichostrongylus L4 and adult O. radiatum were also reduced by 100%, but low prevalence rates in the control animals precluded meaningful statistical inference. Nematode populations for which efficacies ranged from 96.7 to 99.6% (based on geometric means) and for which treatment group differences were significant (P < 0.05) included Ostertagia spp. adult females, inhibited L4 and developing L4, O. ostertagi adult males, Trichostrongylus axei adults and Cooperia spp. adult females. For all nematodes combined, moxidectin was 98.9% efficacious. In addition to exhibiting excellent nematocidal effectiveness, topical moxidectin was demonstrated to be safe, with animal health and milk production unaffected during the study.

The effectiveness of a single treatment with doramectin or ivermectin in the control of gastrointestinal nematodes in grazing yearling stocker cattle.

Four studies were conducted to a similar experimental design in the U.S. to evaluate the effectiveness of doramectin injectable administered to yearling stocker cattle in the control of gastrointestinal nematodiasis over the subsequent grazing period. Studies were conducted in Wisconsin (WI) and Arkansas (AR) during the summer season. The other two studies were conducted in Georgia (GA) and Mississippi (MS) during the winter/spring season. Doramectin was compared with both ivermectin injectable and ivermectin pour-on in the WI study, with ivermectin injectable alone in the GA study and with ivermectin pour-on alone in the other two studies. At each study site, an area of permanent pasture previously grazed by parasitized animals was subdivided by fencing into equal pasture units each with its own water supply. A treatment designation (non-medicated control, doramectin injectable, ivermectin injectable or ivermectin pour-on) was randomly assigned to each pasture unit. Weaned beef calves with confirmed gastrointestinal nematode infections were randomly allotted to a pasture unit and corresponding treatment group. Each treatment group consisted of three replicates of seven animals per pasture unit (total 21 animals) in the WI study, three replicates of four or six animals per pasture unit (total 16 animals) in the AR study, five replicates of six animals per pasture unit (total 30 animals) in the GA study and three replicates of 12 animals per pasture unit (total 36 animals) in the MS study. Treatments were 1% doramectin injectable solution, 1% ivermectin injectable solution, 0.5% ivermectin pour-on solution or non-medicated controls. The injectables were administered at a dose of 1 ml/50 kg body weight (200 micrograms doramectin or ivermectin/kg) by subcutaneous injection in the neck. Ivermectin pour-on solution was administered topically at a dose of 1 ml/10 kg body weight (500 micrograms ivermectin/kg). After receiving their prescribed treatment, animals were placed on their designated pasture unit where they remained for the entire grazing period (84-140 days). Fecal nematode egg counts and body weights were monitored at predetermined intervals throughout each study. Doramectin treatment reduced pretreatment egg counts by between 95 and 100% by 21 days post-treatment. Subsequent rises in egg output from exposure to infective pastures were delayed by two to four weeks resulting in substantial reductions in total egg deposition over the grazing period and, therefore, potential pasture recontamination. Doramectin treatment resulted in substantial average daily weight gain advantages (0.152-0.272 kg) over the grazing season compared to non-medicated controls. Advantages were statistically significant (P < 0.05) in three of the four studies. There were no significant differences (P > 0.05) in average daily gain between the doramectin and ivermectin injectable or ivermectin pour-on treated groups.